China's radiopharmaceuticals on expressway: 2014-2021

This review provides an essential overview on the progress of rapidly-developing China's radiopharmaceuticals in recent years (2014-2021). Our discussion reflects on efforts to develop potential, preclinical, and in-clinical radiopharmaceuticals including the following areas: (1) brain imaging agents, (2) cardiovascular imaging agents, (3) infection and inflammation imaging agents, (4) tumor radiopharmaceuticals, and (5) boron delivery agents (a class of radiopharmaceutical prodrug) for neutron capture therapy. Especially, the progress in basic research, including new radiolabeling methodology, is highlighted from a standpoint of radiopharmaceutical chemistry. Meanwhile, we briefly reflect on the recent major events related to radiopharmaceuticals along with the distribution of major R&D forces (universities, institutions, facilities, and companies), clinical study status, and national regulatory supports. We conclude with a brief commentary on remaining limitations and emerging opportunities for China's radiopharmaceuticals.

Automated summary

This review provides a comprehensive overview of the progress of radiopharmaceuticals in China in recent years, covering various areas such as brain imaging agents, cardiovascular imaging agents, infection and inflammation imaging agents, tumor radiopharmaceuticals, and boron delivery agents. The review highlights the advancements in radiopharmaceutical chemistry and discusses major events, clinical study status, and national regulatory support. The review concludes with a brief commentary on remaining limitations and emerging opportunities for China's radiopharmaceuticals.